evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

632 questions · 636 findings · 33 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 197 · 31%GRADE not reported 13 · 2%Very low 133 · 20.9%Low 159 · 25%Moderate 121 · 19%High 13 · 2%

Summary of findings: tobramycin for inhalation powder vs tobramycin

Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: tobramycin for inhalation powder showed no clear difference in pulmonary exacerbations: number of participants experiencing… compared with tobramycin (moderate certainty).

1 finding from 1 review

Summary of findings: tobramycin for inhalation powder vs tobramycin

Adverse events: number of any adverse event reported · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: tobramycin for inhalation powder showed no clear difference in adverse events: number of any adverse event reported compared with tobramycin (moderate certainty).

1 finding from 1 review

Summary of findings: anti‐pseudomonal antibiotics vs placebo

Frequency of hospital admissions for pulmonary exacerbations ‐ not measured · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: anti‐pseudomonal antibiotics may leads to lower pulmonary exacerbations: frequency of one or more hospital admissions compared with placebo (low certainty).

1 finding from 1 review

Summary of findings: aztreonam lysine for inhalation vs tobramycin

Need for antibiotics see pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: aztreonam lysine for inhalation probably leads to lower pulmonary exacerbations: need for additional antibiotics compared with tobramycin (moderate certainty).

1 finding from 1 review

Summary of findings: aztreonam lysine for inhalation vs tobramycin

Adverse events: number of treatment‐related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: aztreonam lysine for inhalation probably leads to higher adverse events: number of treatment‐related adverse events compared with tobramycin (moderate certainty).

1 finding from 1 review